Skip to main content
OpenTrials

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

15 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Recruiting

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

NCT07075185

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease, +24 more
Locations
  • City of Hope Duarte, California, United States
  • Stanford University Palo Alto, California, United States
  • UCSF San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

NCT05573802

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Corneal Disease, +18 more
Locations
  • General Hospital of Athens "Alexandra", NKUA, Therapeutic Clinic Athens, Greece
  • Anticancer Hospital of Thessaloniki "Theageneio" Thessaloniki, Greece
View Trial Details
Active, not recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Completed

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

NCT05228470

Conditions
BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
Locations
  • Fujian Medical University Union Hospital Fuzhou, Fujian, China
  • Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
View all 15 locations
View Trial Details
Completed

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

NCT01183949

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Centre New York, United States
View Trial Details

Related conditions